This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Why Won't Health Insurance Cover Medical Marijuana?

NEW YORK (TheStreet) -- Two sets of recent poll results suggest that both doctors and the public have come around on the question of cannabis use. But the resurgent Affordable Care Act, which has exceeded its original target for insurance exchange enrollments, offers no relief to patients who struggle to afford the cost of marijuana prescribed by their physicians. And the drug's status, in the eyes of both the federal government and the insurance industry, appears to be caught in a catch-22 of legality and established effectiveness.

On the question of the drug's safety, Pew reports that, "by wide margins, the public views marijuana as less harmful than alcohol, both to personal health and to society more generally." That margin overall is almost five-to-one, and includes majorities of more than two-to-one in every demographic category. Regarding legality, Pew detects "a major shift in attitudes": "As recently as four years ago, about half (52%) said they thought the use of marijuana should not be legal; 41% said marijuana use should be legal. Today those numbers are roughly reversed 54% favor marijuana legalization while 42% are opposed." Medicinal use of marijuana enjoys broad approval, with majorities saying it should be legal in almost every demographic and partisan group.

Meanwhile, an unscientific survey conducted by WebMD set out to test doctors' attitudes toward the drug and found that a majority say "medical marijuana should be legalized nationally and that it can deliver real benefits to patients." Of 1,544 physicians surveyed, 69% said that cannabis "can help with certain treatments and conditions," and 56% supported "making it legal nationwide." Support for medicinal marijuana varied by field, but even among the specialists who expressed the lowest level of approval -- rheumatologists -- a majority favored legalization (54%). Not surprisingly, since marijuana is often used to treat cancer pain and the side effects of chemotherapy, oncologists and hematologists expressed the highest level of support for the drug (82%).

Though medicinal marijuana is legal in 20 states and the District of Columbia, prohibition is still in force at the federal level. Under the Controlled Substances Act of 1970, marijuana is classified as a Schedule I drug, which means that in the government's view it cannot be used safely even under medical supervision. (Cocaine and morphine, by contrast, are Schedule II controlled substances, out of deference to their "currently accepted medical use in treatment.") So according to Uncle Sam, no prescriptions for cannabis can legally be written. Even investigating the drug's medical value is difficult: research-grade marijuana is controlled by the National Institute on Drug Abuse, which is interested in studying addictiveness, not therapeutic potential.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $129.38 0.22%
FB $79.61 -0.18%
GOOG $573.65 0.40%
TSLA $199.54 1.10%
YHOO $42.63 -3.40%

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs